利拉鲁肽对初诊2型糖尿病合并下肢动脉硬化性疾病男性患者白介素-6和股动脉内膜中层厚度的影响  

Effects of Lialulutide on Interleukin-6 and Femoral Artery Intima-Media Thickness in Male Patients with Newly Diagnosed Type 2 Diabetes Mellitus Complicated with Lower Extremity Arteriosclerotic Disease

作　　者：孙艳 代丹娇 陈智伟 张华清 SUN Yan;DAI Danjiao;CHEN Zhiwei;ZHANG Huaqing(Department of Endocrinology,Shenzhen South University of Science and Technology Hospital,Shenzhen 518055,China)

机构地区：[1]南方科技大学医院内分泌科,广东深圳518055

出　　处：《临床医学工程》2020年第8期1009-1010,共2页Clinical Medicine & Engineering

基　　金：深圳市科技创新委员会基础研究自由探索项目“EGF介导自噬途径改善高糖诱导足细胞损伤和凋亡的机制研究”(No:JCYJ20180306170650122)。

摘　　要：目的探讨利拉鲁肽对初诊2型糖尿病(T2DM)合并下肢动脉硬化性疾病(LEAD)男性患者白介素-6 (IL-6)和股动脉内膜中层厚度(IMT)的影响。方法 117例男性T2DM合并LEAD患者随机分为两组,对照组59例予以苯甲酸阿格列汀治疗,试验组58例予以利拉鲁肽治疗,比较两组治疗前后的IL-6及股动脉IMT。结果治疗6个月后,试验组的IL-6及股动脉IMT均显著低于对照组(P <0.05)。结论利拉鲁肽对初诊T2DM合并LEAD男性患者的IL-6有持续改善作用,较短时间使用利拉鲁肽未见股动脉IMT改善,但长期使用股动脉IMT有逆转。Objective To explore the effects of lialulutide on interleukin-6(IL-6)and femoral artery intima-media thickness(IMT)in male patients with newly diagnosed type 2 diabetes mellitus(T2DM)complicated with lower extremity arteriosclerotic disease(LEAD).Methods 117 male patients with T2DM complicated with LEAD were randomly divided into two groups.59 cases in the control group were treated with alogliptin benzoate,and 58 cases in the experimental group were treated with lialulutide.The IL-6 and femoral artery IMT before and after treatment were compared between two groups.Results After treatment for 6 months,the IL-6 and femoral artery IMT of experimental group were significantly lower than those of control group(P<0.05).Conclusions Lialulutide has a continuous improvement effect on IL-6 in male patients with newly diagnosed T2DM combined with LEAD.No improvement in femoral artery IMT is observed after short-term use of liraglutide,but femoral artery IMT can be reversed after long-term use of liraglutide.

关 键 词：利拉鲁肽 2型糖尿病 下肢动脉硬化性疾病 白介素-6 股动脉内膜中层厚度 

分 类 号：R969.4[医药卫生—药理学]